Scientific Organising Committee
- Dr Jordi Gracia-Sancho, Spain
- Dr Mercedes Fernández, Spain
Cells composing the liver microvasculature play essential roles in the pathophysiology of liver diseases, and therefore their study at the bench-side results essential to understand disease biology and to develop new therapeutics. The 2018 Basic School of Hepatology will provide updated information about how to properly characterize liver vascular cells phenotype, function, and interactions, combining state of the art lectures, short seminars, and extensive hands-on practices. In addition, soft practical exercises will focus on the improvement of scientific communication skills. A major aim of the School is to potentiate close interaction between faculty and participants, therefore a reduced number of applicants (maximum 36) will be selected to be part of this experience. The School will be developed at the IDIBAPS Biomedical Research Center in Barcelona.
- Recognize the cellular components of the liver microvasculature, their characteristics, and interactions, in health and disease.
- Understand the variety of techniques available to comprehensibly characterize the phenotype of the liver microvasculature.
- Be able to design an experimental research project to solve a relevant question in the field of liver vascular diseases.
- Be able to summarize your research project in a 5min elevator pitch.
About EASL Schools
The schools contribute to the training of new generations of hepatologists and are a major element of our association. Aimed at young fellows enrolled in hepatology-oriented departments or more experienced clinicians who want to be exposed to the newest trends in hepatology.
For selected applicants, EASL will cover transportation costs to attend the school and accommodation during the event (details will be provided individually once the selection process has been done).
Application is open to young fellows under the age of 35 and/or still in training.
Approximately 30 places are available for each school and priority is given to registered EASL members during the selection process.
Supported by AbbVie, Bristol-Myers Squibb and MSD who provided funding.
AbbVie, Bristol-Myers Squibb and MSD have had no input into the content of the materials and presentations used at this event.